Celon Pharma S.A. (WSE:CLN)

Celon Pharma Statistics

Total Valuation

Celon Pharma has a market cap or net worth of PLN 1.14 billion. The enterprise value is 1.18 billion.

Market Cap	1.14B
Enterprise Value	1.18B

Important Dates

The next confirmed earnings date is Wednesday, September 16, 2026.

Earnings Date	Sep 16, 2026
Ex-Dividend Date	n/a

Share Statistics

Celon Pharma has 53.86 million shares outstanding. The number of shares has decreased by -2.06% in one year.

Current Share Class	38.86M
Shares Outstanding	53.86M
Shares Change (YoY)	-2.06%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	10.33%
Float	23.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	344.36
PS Ratio	5.02
PB Ratio	2.92
P/TBV Ratio	2.94
P/FCF Ratio	n/a
P/OCF Ratio	2,402.48
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-9.68
EV / Sales	5.22
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-28.66

Financial Position

The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.04.

Current Ratio	1.90
Quick Ratio	1.38
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.34
Interest Coverage	-74.93

Financial Efficiency

Return on equity (ROE) is -26.97% and return on invested capital (ROIC) is -29.88%.

Return on Equity (ROE)	-26.97%
Return on Assets (ROA)	-12.81%
Return on Invested Capital (ROIC)	-29.88%
Return on Capital Employed (ROCE)	-26.81%
Weighted Average Cost of Capital (WACC)	8.19%
Revenue Per Employee	399,906
Profits Per Employee	-215,747
Employee Count	566
Asset Turnover	0.42
Inventory Turnover	2.82

Taxes

Income Tax	-4.06M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.05% in the last 52 weeks. The beta is 0.72, so Celon Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.72
52-Week Price Change	-7.05%
50-Day Moving Average	20.81
200-Day Moving Average	21.57
Relative Strength Index (RSI)	53.10
Average Volume (20 Days)	7,506

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celon Pharma had revenue of PLN 226.35 million and -122.11 million in losses. Loss per share was -2.35.

Revenue	226.35M
Gross Profit	154.88M
Operating Income	-111.80M
Pretax Income	-126.17M
Net Income	-122.11M
EBITDA	-82.20M
EBIT	-111.80M
Loss Per Share	-2.35

Balance Sheet

The company has 21.03 million in cash and 14.19 million in debt, with a net cash position of 6.84 million or 0.13 per share.

Cash & Cash Equivalents	21.03M
Total Debt	14.19M
Net Cash	6.84M
Net Cash Per Share	0.13
Equity (Book Value)	389.19M
Book Value Per Share	7.23
Working Capital	48.79M

Cash Flow

In the last 12 months, operating cash flow was 473,000 and capital expenditures -41.70 million, giving a free cash flow of -41.23 million.

Operating Cash Flow	473,000
Capital Expenditures	-41.70M
Depreciation & Amortization	29.59M
Net Borrowing	-10.33M
Free Cash Flow	-41.23M
FCF Per Share	-0.77

Margins

Gross margin is 68.43%, with operating and profit margins of -49.39% and -53.95%.

Gross Margin	68.43%
Operating Margin	-49.39%
Pretax Margin	-55.74%
Profit Margin	-53.95%
EBITDA Margin	-36.32%
EBIT Margin	-49.39%
FCF Margin	n/a

Dividends & Yields

Celon Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.06%
Shareholder Yield	2.06%
Earnings Yield	-10.75%
FCF Yield	-3.63%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3